person
as of 2026-07-01Daniel C. Javitt, MD, PhD
Daniel C Javitt, MDDaniel C Javitt, MD PhDDaniel C Javitt, MD, PhDDaniel Javitt, MD, PhD
ORCID 0000-0003-2711-8239
at a glance
Roles: Principal Investigator, Author
KOL signal score 8
2 publications · 0 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Nathan Kline Institute, New York State Psychiatric Institute
Roles
Principal Investigator, Author
KOL signal
8
Publications
2 (0 high-value)
Trial investigator
yes
Publishes on
1 drugs
Trials led
8
Biomarkers in Schizophrenia
NCT00817336Phase 2Completed
TDCS for Auditory Hallucinations in Schizophrenia
NCT01898299—Completed
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
NCT07469384—Recruiting
Remediation of Auditory Recognition in Schizophrenia With tDCS
NCT02869334—Completed
D-serine for the Schizophrenia Prodrome
NCT00826202Phase 2Completed
Sodium Oxybate in Schizophrenia With Insomnia
NCT00594256Phase 2Completed
A Multicenter Study of NAP (AL-108) in Schizophrenia
NCT00505765Phase 2Completed
Safety and Effectiveness of D-serine in Schizophrenia
NCT00322023Phase 2Completed
Publications & congress
2
Serotonin type 3 receptor (5-HT
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?
The American journal of psychiatry · 2025
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
PRINCIPAL_INVESTIGATOR